Implanet 2019 Revenue up 10% to €7.40 Million With Q4 Growth of 20%

Regulatory News:

IMPLANET (Paris:ALIMP) (OTCQX:IMPZY) (Euronext Growth: ALIMP, FR0010458729, eligible for PEA-PME equity savings plans; OTCQX: IMPZY) (the “Company”), a medical technology company specializing in vertebral and knee-surgery implants, today announced its revenue for the fourth quarter and for the financial year ended December 31^st, 2019.

Ludovic Lastennet, Implanet’s Chief Executive Officer, commented: “We finished the year as expected with a strong Q4 surge in revenue growth. 2019 revenue therefore confirms the positive trend initiated in the first quarter. The partnerships signed, and initial orders with KICo Knee and SeaSpine this year in our two business lines together with the first successful JAZZ Cap surgeries, the patents obtained for JAZZ Lock in Japan and the USA and the first 510(k) clearance for the MADISON knee prosthesis in the USA are further strengths that will help drive the future business development. This year’s growth in both business segments is tangible proof that our efforts and initiatives are beginning to pay off. We remain realistic about our future roadmap and enter the new year determined to continue these efforts and sales initiatives in order to boost profitability and consolidate this strong momentum.”

Revenue (€ ‘000s - IFRS*)	2019	2018	Change
First-quarter revenue	1,904	1,867	+2%
Second-quarter revenue	1,915	1,765	+8%
Third-quarter revenue	1,739	1,548	+12%
Spine (JAZZ)	979	841	+16%
Knee	871	699	+25%
Total fourth-quarter revenue	1,850	1,540	+20%
Spine (JAZZ)